课题基金 / 基金详情

Development of a novel gene therapy technology for site-specific integration of large-sized genes

Development of a novel gene therapy technology for site-specific integration of large-sized genes
开发用于大尺寸基因位点特异性整合的新型基因治疗技术
批准号:
08457280
负责人:
OZAWA Keiya
金额:
$4.54万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
1996
资助国家:
日本
项目状态:
已结题
起止时间:
1996 至 1997

项目摘要

项目成果

OZAWA Keiya的其他基金

相似基金

相关文献

中文摘要
翻译
用于基因治疗的理想的基因递送系统应具有几个特征,包括1)以可预测的或位点特异性的方式将递送的基因整合到靶基因组中,2)转基因的长期表达,和3)递送足够大尺寸的DNA序列以包括所有调节元件的能力。一种新的基因传递系统,称为靶向载体整合(TVI)的发展,目前正在进行中,以满足上述先决条件。该系统基于腺相关病毒(AAV),其优先整合到人类基因组中位于染色体19(19q13.3-qter)上的定义的基因座(称为AAVI 1)处。AAV-Rep蛋白被认为介导含有AAV-ITR(反向末端重复)的DNA序列整合到AAVS 1基因座中,通过在ITR内的GAGC重复和AAVS 1基因座中的相似序列之间形成复合物。有4种不同的Rep蛋白(Rep 78、Rep 68、Rep 52和Rep 40)。为了确定赋予ITR连锁基因位点特异性整合能力的Rep,我们构建了表达单个Rep蛋白的各种质粒。将这些质粒与含有侧接ITR的LacZ表达盒的质粒共转染到293细胞中。进行基于PCR的斑点印迹分析、Southern分析和FISH分析以检测位点特异性整合。结果表明,大Rep(78或68)是ITR连锁基因位点特异性整合所必需的。此外,具有R107 A、K136 A或R138 A的突变体Rep蛋白显示与GAGC重复序列的结合降低,并且没有切口活性。这些突变体也失去了位点特异性整合活性。本研究对开发更精细的TVI系统具有一定的参考价值。
英文摘要
The desirable gene-delivery system for gene therapy should have several features, including 1) integration of the delivered gene in a predictable or site-specific manner into the target genome, 2) long-term expression of the transgene, and 3) the ability to deliver DNA sequences of sufficiently large size to include all the regulatory elements. The development of a novel gene delivery system, termed targeted vector integration (TVI), is currently in progress to fulfilll the above prerequisites. The system is based on adeno-associated virus (AAV) which preferentially integrates into the human genome at a defined locus, called AAVI1, on chromosome 19 (19q13.3-qter). The AAV-Rep proteins are considered to mediate integration of DNA sequence containing AAV-ITR (inverted terminal repeat) into AAVS1 locus, through the formation of a complex between GAGC repeats within ITR and a similar sequence in AAVS1 locus. There are 4 different Rep proteins (Rep78, Rep68, Rep52, and Rep40). Aiming at determining the Rep (s), which confer the ability of site-specific integration of ITR-linked genes, we constructed various plasmids that express individual Rep proteins. These plasmids were co-transfected into 293 cells with the plasmid containing a LacZ expression cassette flanked by ITRs. A PCR-based dot blot assay, Southern analysis, and FISH analysis were conducted to detect site-specific integration. The results showed that the large Rep (78 ot 68) is necessary for the site-specific integration of ITR-linked genes. In addition, mutant Rep proteins with R107A,K136A,or R138A showed the decreased binding to GAGC repeat and no nicking activity. These mutants also lost the site-specific integration activity. The present study will be valuable to develop the more refined TVI system.
期刊论文(25)
专著(0)
科研奖励(0)
会议论文
Yoshikazu Maeda: "Gene transfer into vascular cells using adeno-associated virus(AAV)vectors" Cardiovascular Res.35. 514-521 (1997)
Yoshikazu Maeda:“使用腺相关病毒 (AAV) 载体将基因转移到血管细胞”Cardioangio Res.35。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
22
    Development of a site-specific gene insertion technology for regenerative medicine:Basic study using developmental engineering
    • 批准号:
      23659493
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.33万
    • 财政年份:
      2011
    • 负责人:
      OZAWA Keiya
    • 依托单位:
    Development of gene therapy using bone-marrow-derived mesenchymal stem cells
    • 批准号:
      21390296
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.4万
    • 财政年份:
      2009
    • 负责人:
      OZAWA Keiya
    • 依托单位:
    Development of gene therapy for malignant lymphoma using mesenchymal stem cells with tumor-accumulating capacity
    • 批准号:
      19390267
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.73万
    • 财政年份:
      2007
    • 负责人:
      OZAWA Keiya
    • 依托单位:
    Development of AAV (adeno-associated virus) vectors and their application to cancer therapy
    • 批准号:
      17016067
    • 项目类别:
      Grant-in-Aid for Scientific Research on Priority Areas
    • 资助金额:
      $42.88万
    • 财政年份:
      2005
    • 负责人:
      OZAWA Keiya
    • 依托单位:
    海外基金